Pomalidomide for the treatment of relapsed and refractory multiple myeloma

Anna Guidetti, Claudia Paba Prada, Jacob P. Laubach, Cindy Varga, Michelle E. Maglio, Mary McKenney, Deborah Doss, Robert L. Schlossman, Constantine Mitsiades, Teru Hideshima, Gullu Gorgun, Irene M. Ghobrial, Noopur Raje, Nikhil Munshi, Kenneth C. Anderson, Paul G. Richardson

Research output: Contribution to journalArticle

Abstract

Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is unique in that it demonstrates promising activity but appears to be associated with lower toxicity than thalidomide or lenalidomide. Areas covered: We review the mechanisms of action of pomalidomide, evaluate preclinical data, summarize the results of dose-finding Phase I studies and describe Phase II/III studies of this drug in combination with dexamethasone and other agents. Data presented were gathered from multiple sources, including articles from PubMed, published abstracts from the annual meetings of the American Society of Hematology and American Society of Clinical Oncology and websites such as http://clinicaltrials.gov/. Expert opinion: The regulatory approval of pomalidomide represents an important addition to a hematologist's armamentarium for the treatment of RRMM. Pomalidomide is well tolerated and demonstrates a high level of anti-myeloma activity. Pomalidomide combined with dexamethasone should be considered as standard-of-care therapy for advanced RRMM following progression on both lenalidomide and bortezomib. Ongoing and future studies will characterize the activity of different combinations intended to improve treatment responses, and the potential role of pomalidomide as maintenance therapy.

Original languageEnglish (US)
Pages (from-to)1089-1108
Number of pages20
JournalExpert Opinion on Orphan Drugs
Volume2
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Multiple Myeloma
Dexamethasone
Therapeutics
Thalidomide
Expert Testimony
Drug Combinations
Standard of Care
PubMed
pomalidomide
lenalidomide

Keywords

  • Immunomodulatory drugs
  • Multiple myeloma
  • Pomalidomide
  • Relapsed and refractory

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Guidetti, A., Paba Prada, C., Laubach, J. P., Varga, C., Maglio, M. E., McKenney, M., ... Richardson, P. G. (2014). Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs, 2(10), 1089-1108. https://doi.org/10.1517/21678707.2014.953480

Pomalidomide for the treatment of relapsed and refractory multiple myeloma. / Guidetti, Anna; Paba Prada, Claudia; Laubach, Jacob P.; Varga, Cindy; Maglio, Michelle E.; McKenney, Mary; Doss, Deborah; Schlossman, Robert L.; Mitsiades, Constantine; Hideshima, Teru; Gorgun, Gullu; Ghobrial, Irene M.; Raje, Noopur; Munshi, Nikhil; Anderson, Kenneth C.; Richardson, Paul G.

In: Expert Opinion on Orphan Drugs, Vol. 2, No. 10, 01.10.2014, p. 1089-1108.

Research output: Contribution to journalArticle

Guidetti, A, Paba Prada, C, Laubach, JP, Varga, C, Maglio, ME, McKenney, M, Doss, D, Schlossman, RL, Mitsiades, C, Hideshima, T, Gorgun, G, Ghobrial, IM, Raje, N, Munshi, N, Anderson, KC & Richardson, PG 2014, 'Pomalidomide for the treatment of relapsed and refractory multiple myeloma', Expert Opinion on Orphan Drugs, vol. 2, no. 10, pp. 1089-1108. https://doi.org/10.1517/21678707.2014.953480
Guidetti A, Paba Prada C, Laubach JP, Varga C, Maglio ME, McKenney M et al. Pomalidomide for the treatment of relapsed and refractory multiple myeloma. Expert Opinion on Orphan Drugs. 2014 Oct 1;2(10):1089-1108. https://doi.org/10.1517/21678707.2014.953480
Guidetti, Anna ; Paba Prada, Claudia ; Laubach, Jacob P. ; Varga, Cindy ; Maglio, Michelle E. ; McKenney, Mary ; Doss, Deborah ; Schlossman, Robert L. ; Mitsiades, Constantine ; Hideshima, Teru ; Gorgun, Gullu ; Ghobrial, Irene M. ; Raje, Noopur ; Munshi, Nikhil ; Anderson, Kenneth C. ; Richardson, Paul G. / Pomalidomide for the treatment of relapsed and refractory multiple myeloma. In: Expert Opinion on Orphan Drugs. 2014 ; Vol. 2, No. 10. pp. 1089-1108.
@article{87f3e3460b484cb389e944fe71ea8a30,
title = "Pomalidomide for the treatment of relapsed and refractory multiple myeloma",
abstract = "Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is unique in that it demonstrates promising activity but appears to be associated with lower toxicity than thalidomide or lenalidomide. Areas covered: We review the mechanisms of action of pomalidomide, evaluate preclinical data, summarize the results of dose-finding Phase I studies and describe Phase II/III studies of this drug in combination with dexamethasone and other agents. Data presented were gathered from multiple sources, including articles from PubMed, published abstracts from the annual meetings of the American Society of Hematology and American Society of Clinical Oncology and websites such as http://clinicaltrials.gov/. Expert opinion: The regulatory approval of pomalidomide represents an important addition to a hematologist's armamentarium for the treatment of RRMM. Pomalidomide is well tolerated and demonstrates a high level of anti-myeloma activity. Pomalidomide combined with dexamethasone should be considered as standard-of-care therapy for advanced RRMM following progression on both lenalidomide and bortezomib. Ongoing and future studies will characterize the activity of different combinations intended to improve treatment responses, and the potential role of pomalidomide as maintenance therapy.",
keywords = "Immunomodulatory drugs, Multiple myeloma, Pomalidomide, Relapsed and refractory",
author = "Anna Guidetti and {Paba Prada}, Claudia and Laubach, {Jacob P.} and Cindy Varga and Maglio, {Michelle E.} and Mary McKenney and Deborah Doss and Schlossman, {Robert L.} and Constantine Mitsiades and Teru Hideshima and Gullu Gorgun and Ghobrial, {Irene M.} and Noopur Raje and Nikhil Munshi and Anderson, {Kenneth C.} and Richardson, {Paul G.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1517/21678707.2014.953480",
language = "English (US)",
volume = "2",
pages = "1089--1108",
journal = "Expert Opinion on Orphan Drugs",
issn = "2167-8707",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Pomalidomide for the treatment of relapsed and refractory multiple myeloma

AU - Guidetti, Anna

AU - Paba Prada, Claudia

AU - Laubach, Jacob P.

AU - Varga, Cindy

AU - Maglio, Michelle E.

AU - McKenney, Mary

AU - Doss, Deborah

AU - Schlossman, Robert L.

AU - Mitsiades, Constantine

AU - Hideshima, Teru

AU - Gorgun, Gullu

AU - Ghobrial, Irene M.

AU - Raje, Noopur

AU - Munshi, Nikhil

AU - Anderson, Kenneth C.

AU - Richardson, Paul G.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is unique in that it demonstrates promising activity but appears to be associated with lower toxicity than thalidomide or lenalidomide. Areas covered: We review the mechanisms of action of pomalidomide, evaluate preclinical data, summarize the results of dose-finding Phase I studies and describe Phase II/III studies of this drug in combination with dexamethasone and other agents. Data presented were gathered from multiple sources, including articles from PubMed, published abstracts from the annual meetings of the American Society of Hematology and American Society of Clinical Oncology and websites such as http://clinicaltrials.gov/. Expert opinion: The regulatory approval of pomalidomide represents an important addition to a hematologist's armamentarium for the treatment of RRMM. Pomalidomide is well tolerated and demonstrates a high level of anti-myeloma activity. Pomalidomide combined with dexamethasone should be considered as standard-of-care therapy for advanced RRMM following progression on both lenalidomide and bortezomib. Ongoing and future studies will characterize the activity of different combinations intended to improve treatment responses, and the potential role of pomalidomide as maintenance therapy.

AB - Introduction: Multiple myeloma patients who are refractory to lenalidomide and bortezomib have a dismal prognosis. Pomalidomide is a new immunomodulatory agent approved for the treatment of relapsed and refractory multiple myeloma (RRMM) that is unique in that it demonstrates promising activity but appears to be associated with lower toxicity than thalidomide or lenalidomide. Areas covered: We review the mechanisms of action of pomalidomide, evaluate preclinical data, summarize the results of dose-finding Phase I studies and describe Phase II/III studies of this drug in combination with dexamethasone and other agents. Data presented were gathered from multiple sources, including articles from PubMed, published abstracts from the annual meetings of the American Society of Hematology and American Society of Clinical Oncology and websites such as http://clinicaltrials.gov/. Expert opinion: The regulatory approval of pomalidomide represents an important addition to a hematologist's armamentarium for the treatment of RRMM. Pomalidomide is well tolerated and demonstrates a high level of anti-myeloma activity. Pomalidomide combined with dexamethasone should be considered as standard-of-care therapy for advanced RRMM following progression on both lenalidomide and bortezomib. Ongoing and future studies will characterize the activity of different combinations intended to improve treatment responses, and the potential role of pomalidomide as maintenance therapy.

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - Pomalidomide

KW - Relapsed and refractory

UR - http://www.scopus.com/inward/record.url?scp=84911460574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911460574&partnerID=8YFLogxK

U2 - 10.1517/21678707.2014.953480

DO - 10.1517/21678707.2014.953480

M3 - Article

AN - SCOPUS:84911460574

VL - 2

SP - 1089

EP - 1108

JO - Expert Opinion on Orphan Drugs

JF - Expert Opinion on Orphan Drugs

SN - 2167-8707

IS - 10

ER -